A beta blocker typically used to treat heart problems, hemangioma, migraines and anxiety could be a new therapeutic for patients with sickle cell disease. Researchers led by Ankit A. Desai, MD, associate professor of medicine at the Krannert Cardiovascular Research Center (KCVRC) at Indiana University School of Medicine, have been awarded a $3 million grant by the U.S. Department of Defense to evaluate the efficacy of this drug.
MR-linac systems could help clinicians distinguish true progression from pseudoprogression in glioblastoma
Is it true progression or pseudoprogression in tumor growth?
October 3, 2023